Follicular Response by Using Letrozole

Follicular Response by Using Letrozole Alone or Combination of Letrozole and Gonadotrophins in Patients Stimulated For Intrauterine Insemination Introduction: Throughout history, human societies were preoccupied by the process of procreation which they attempted to describe through art and religion. It is one of the major aspects of maintaining survival and perpetuation of the human race. In view of the entwined nature between sexuality, morality, and reproduction, fertility played a pivotal role in almost all religions on this Earth.

As described in the Bible, and in numerous historical documents, infertility problems have played a central role in the relationship between man and woman, since time immemorial, and both laws and religions have been used to regulate right and wrong in relations between married couples who face infertility (divorce, multiple marriages among Muslims, adoption, suicide, etc).

The number of subfertile couples is increasing numerically in an expanding global population, even if infertility per se does not increase. Unfortunately, factors such as environmental pollution and sexually transmittable diseases tend to further exacerbate the problems in certain parts of the world, especially in developing countries, where they are predominantly associated with secondary infertility. 1 Bangladesh is a developing country with an exploding population of 158 million, a total fertility rate of 2.74 per thousand live births and a growth rate of 1.292 %. 2 In spite of that, there are a large number of couples who remain childless for years together. Sub fertility in a woman does not claim her life or maim her physically, but she suffers from psychological trauma of being unable to fulfil her biological role of being a mother, which is more pronounced in Asian and African countries. It becomes worse if she has to bear the humiliation on behalf of her husband, who could be the cause of infertility.

Prevalence of infertility in developing countries is difficult to assess due to inconsistencies in defining infertility. Between 8% - 12% of couples around the world have difficulty in conceiving a child at some points in their life.3 Data from U.S. National survey of family growth indicate that the prevalence of infertility was 13.35% in 1965, and 13.9 % in 1988. 4 Although the overall prevalence of infertility in USA has not been changed since 1965, but the demand for infertility care has increased significantly in the last few decades. Data from U.S. National survey of Family Growth1995- showed that 13% had sought medical attention for infertility in their lifetime.5 The Indian reports, both from the institute for Research in reproduction, Mumbai and from Mehta et al, Bangalore 6 seem to agree that the declining trend of semen quality over the years is responsible for increased male factor infertility. 6 In a study of rural population of Bangladesh 3.2% of married women of reproductive age have primary infertility and 3% have secondary infertility. 7 Majority of infertile women (40%) believed this to be their fate and 33% accused themselves for infertility. 7 Prior to 1960s, infertility was almost exclusively a diagnostic statement with no treatment possibilities. It is well known that mechanical, hormonal, and psychological factors, in either

the female or male partner could be responsible for infertility. Sometimes, more than one of these factors is involved, which thus become obvious during the workup of the couple, but reasonably often, no explanation for the infertility could be found, a condition referred to as ‘unexplained infertility. It was believed that perhaps, more diffuse psychological factors played a predominant role in these cases.

Technical innovations in the laboratory and by the pharmaceutical industry have helped to promote the success rate of infertility treatment. The introduction of invitro fertilization & embryo transfer (IVF-ET) in 1980s has made it possible for the couple to take advantage of this technology. Winning of Nobel Prize of the year 2010 for the 1 st successful IVF was the golden recognition of this method by the world. Though Vatican City & activist Muslims are yet against IVF-ET, but for some subfertile couples, it is their only hope.

The true clinical meanings of terms such as ‘Pregnancy rates’ or ‘the chances of success’ must be explained thoroughly while counselling a couple – which can be explained in medical science by words – fecundability and fecundity. Fecundability refers to the probability that actions taken during one menstrual cycle will result in a pregnancy.

Fecundity is the possibility that actions taken during a single menstrual cycle will result in a live birth. Fecundity in women at the age of 20 is approximately 15% to 20% per cycle – whereas the fecundity in infertile couples can be as low as 1% to 3%. A marked decrease in fecundity with advancing age has been documented. Data from studies have suggested that fertility of women generally peaks between ages 20 and 24.8 WHO task force on the diagnosis and treatment of infertility in 1992 divided the infertility issue into male factors and female factors. The actual percentages of the individual factors that are found to be the primary cause of infertility vary widely between studies.9However in a broad Meta analysis of more than 20 trials studying infertile couples, the following primary diagnosis was found: Disorders of ovulation (27%), abnormal semen parametres (25%), abnormalities of the fallopian tube (22%), unexplained infertility (17%), endometriosis (5%) and others (4%).10 In couples of idiopathic or unexplained infertility, Assisted Reproductive Technologies may offer a non specific enhancement of cycle fecundity. The number of assisted reproductive technologies available as well as their use has dramatically increased since the birth of Louis Brown in 1978 from IVF-ET. Controlled ovarian hyper stimulation combined with IUI of capacitated sperm (COH-IUI) has recently been used to treat a subset of couples infertile in the absence of mechanical compromise of the pelvic viscera, in whom no other efficacious treatment options exist . 11, 12, 13 This approach has four potential advantages over simply awaiting the infrequent spontaneous conception, that is expected management. These include (1) increasing the number of oocytes available for fertilization; (2) increasing the levels of follicular and lutial phase gonadal steroids; (3) optimising the likelihood of gamete interaction with viable oocytes and sperm virtually guaranteed to be simultaneously present in the female genital tract; and (4) providing large numbers of capacitated sperm at the site of fertilization in the distal fallopian tubes. Many of these features are common to the more invasive oocyte retrieval techniques such as IVF-ET, gamete intra fallopian transfer (GIFT), zygote intra fallopian transfer (ZIFT).11 The major difference with COH-IUI is that the normal fallopian tubes can be anticipated to function appropriately and no surgical procedure is required to collect oocytes. The initial suggestion that COH-IUI might be efficacious was based on the occasional pregnancies observed in women in IVF-ET programs when the oocyte retrieval

was cancelled because of poor follicular recruitment and IUI substituted in an effort to salvage some benefit from the cycle. This therapy quickly became a popular therapeutic option because of the relatively lower cost, the avoidance of oocyte retrieval and laparoscopy and as cycle fecundity comparable with the other assisted reproductive technologies.

IUI is the best-studied and most widely practiced technique for mild to moderate male factor infertility. In a review, Hamburg and Insler 14 concluded that, taking into account efficacy, complication rates and cost of infertility treatment women with hypogonadotrophic hypogonadism or polycystic ovary syndrome (PCOS) should be offered acceptable methods of ovulation induction and that couples with ‘unexplained’ or ’multifactorial subfertility’ should be exposed to controlled ovarian hyperstimulation with IUI (COH IUI) and only after the failure of these therapies should be offered invitro fertilization (IVF).14 To perform COH with IUI, at least one patent tube and some ovarian function in female and motile sperm in male should present.15 IUI is a fertility enhancing procedure in which sperms are prepared by washing, swim up and swim down techniques and by use of density gradients. 16 The washing procedures are necessary to remove prostaglandin, infectious agents, antigenic proteins, nonmotile spermatozoa, leukocytes, and immature germ cells. Concentrated germ cells are inseminated directly into a woman’s uterus through the cervix. Intrauterine insemination increases the number of potent sperm by decreasing the formation of free radicals after sperm preparation, in the uterus and fallopian tubes- where fertilization takes place. The final result is an improved fertilizing capacity of the sperm in vitro and in vivo fertilization. 17 The use of washed sperm reduces painful uterine cramps, collapse and infection. 16 Controlled ovarian hyperstimulation (COH) has got the primary cycle fecundity enhancing effect due to the increase in the number of oocytes released in a given cycle for ovulation induction. For controlled ovarian stimulation in IUI cycles many ovulation induction protocol have been devised. Such as Clomiphene citrate, Aromatase inhibitor (Letrozole) alone or in combination with Gonadotrophins (hMG or rFSH), human chorionic Gonadotrophins (hCG); and the use of Gonadotrophin releasing agonist or antagonist combined with Gonadotrophins. hCG is usually used at the end of the stimulation phase to achieve final maturation of the oocytes.16 No well designed comparative trials have been performed to determine if one regimen is superior to another. By Clomiphene citrate (Cc), though follicular development is higher, but due to the potentially adverse effect on the oestrogen-responsive tissue in the genital tract, such as the cervical mucus, endometrium, and fallopian tubes, it yields a somewhat lower cycle fecundity than when the COH is induced with hMG., Letrozole hMG may offer some advantages in selected couples, reducing the dose of hMG required to achieve optimal stimulation. Letrozole stimulates an early follicular rise in the endogenous gonadotrophins, whereas hMG provides an increase in exogenous gonadotrophins later in the stimulation course. Injection hCG is administered at the end of induction for final maturation and luteal support. The addition of IUI to Letrozole increase fecundity in couples with unexplained infertility or surgically treated endometriosis.18, 19 As with almost all infertility, success is age related with pregnancy rates 3-4 fold greater in women under age 20. Ovarian stimulation with letrozole is associated with acceptable pregnancy rates compared with gonadotrophin (cumulative pregnancy rate per couple: 24% vs. 36%), 20 with significant less cost, risk and patient inconvenience.

Rationale of the study Bangladesh is a country of 158 million people. The number of subfertile couples seeking treatment is increasing day by day. Different infertility clinics are providing various modalities of treatment. IUI is one of the most popular treatments in our country. Mild to

moderate male factor subfertility can be overcome by COH and IUI. Although there are a large number of studies on COH and IUI internationally, there are no studies in our country.

The present study was conducted to determine the follicular response by different types of ovulation inducing drugs, the effectiveness of IUI and COH and its outcome and also to assess the cost effectiveness in a tertiary level infertility management centre in our country.

Hypothesis and objective Of the Study Hypothesis: Induction of ovulation by gonadotrophins along with letrozole gives better follicular development than letrozole alone in stimulated IUI cycles.

Objective of the study: General objective: To assess the follicular response by Letrozole alone or by combination of Letrozole and Gonadotrophins in patients stimulated for IUI. Specific objective: •

To compare the follicular response by Letrozole alone or by combination of Letrozole and Gonadotrophins.

•

To compare the follicular response by giving Letrozole alone in <30 years and >30 years patients.

•

To compare the follicular response by giving combination of Letrozole and Gonadotrophins in IUI cycle in these two groups of patients.

Literature review Causes of infertility and subfertility: One of the broadest investigations conducted by WHO task force on the diagnosis and treatment of infertility in 199221 has shown several significant differences in their findings depending on the economic environment of the populations studied. But the data was remarkably uniform.

1. Abnormalities of sperm production (Male Factor)

i) Abnormalities in hormonal support of spermatogenesis ii) Abnormalities in spermatogenesis iii) Obstruction of outflow tract iv) Inability to perform successful coitus

2. Abnormalities in the ability to produce a fertilizable oocyte (Ovulatory Factor)

i) Gonadal disgenesis(Turnerâ&#x20AC;&#x2122;s Syndrome) ii) Premature ovarian failure iii)

Lutinized unruptured follicle syndrome

iv)Depletion of oocyte pool by:

a. Pelvic Surgery b. Endometriosis c. Infection, TB d. Chemotherapy

3. Abnormalities of the female reproductive tract

i) Tubal Factor ii)

Peritoneal Factor

iii)

Uterine Factor

iv)Cervical Factor

4. Abnormalities of implantation

i) Luteal phase defect ii)

Hyperprolactinaemia

iii)

Insuline Resistance

iv)Embryo-endometrial factor v) Abnormalties of early embryogenesis

5. Immunologic Factors

i) Autoimmune diease ii) Anti-phospholipid syndrome iii)

Thrombophilias

iv)Recurrent pregnancy loss

Intrauterine insemination An overview: Artificial insemination is an assisted reproduction method that can be used to alleviate infertility in selected couples. The rationale behind the use of IUI is to increase the sperm density near the site of fertilization. 22 It is generally accepted that IUI should be preferred to more invasive and expensive techniques of assisted reproduction (ART) and be offered as a first choice treatment in cases of unexplained and moderate male factor infertility and cervical factor infertility. 23 The benefit of IUI in male factor infertility has been accepted because IUI appears to result in higher pregnancy rates than natural intercourse or intracervical insemination (OR 2.20, 95% CI 1.43-3.39). Hamburg and Insler concluded that taking into account- efficacy, complication rates and cost effectiveness of treatment, women with hypogonadotrophic hypogonadism or PCOS should be offered acceptable methods of ovulation induction and that couples with unexplained and multifactorial infertility should be exposed to controlled ovarian stimulation with IUI and only after the failure of these therapies IVF should be offered.14 The use of IUI reduces the normal attrition of sperm as they ascend through the female genital tract and thus guarantees a large numbers of capacitated sperm at the site of fertilization in the distal ampulla of the fallopian tube. 16 This is similar to what is accomplished in IVF-ET and GIFT, when higher sperm densities are used during the oocyte incubation (IVF), or placed retrograde in the fallopian tube (GIFT). 24 IUI is a distinctly nonphysiological process. However, after the IUI, the sperm are physiologically capacitated by their passage through the genital tract.

IUI is a relatively simple procedure compared with IVF, and its popularity as a treatment option for certain diagnostic groups of infertile couples is increasing, since it is the intermediate between simple ovulation induction and the more â&#x20AC;&#x153;high techâ&#x20AC;? IVF. This is particularly so in developing countries, where the facilities for IVF may be limited, and the cost of treatment is a major issue. There are continuing discussions in the literature about whether or not IUI should be complimented by ovulation induction. Most practitioners are of the opinion that IUI with ovulation induction does increase the success rate, and many will initially try with Clomiphene Citrate or Letrozole, and move on to Gonadotrophins, if there is no success within a few cycles. The most appropriate time to move on from IUI to IVF is a matter of debate, but most agree that change should be made from no more than 4-6 cycles of IUI. Before proceeding to IUI couples should undergo a complete assessment, which should include thorough medical history, physical examination and investigations. Tubal patency

must be tested by laparoscopy or hysterosalpingography. It is essential that couples should receive adequate counselling prior to starting treatment, and also be assured of complete confidentiality, and informed consent should be taken. All the pros and cons of IUI should be disclosed to the couple.

Indication of IUI: There are a number of indications for IUI using the husband’s or partner/donor’s (not accepted in our country) semen. The most common indications are listed below:

Effective: •

Male subfertility (oligozoospermia/asthenozoospermia/ terratozoospermia)

•

Cervical Factor subfertility

•

Immunology subfertility

•

Ejaculatory failure (hypospadius, retrograde ejaculation)

•

Unexplained infertility

•

Mild Endometriosis

•

Polycystic Ovary Syndrome (PCOS)

Timing of Insemination: The ideal timing for IUI should be 36 to 40 hours after the ovulating dose of hCG, ensuring that sperm and oocytes are present simultaneously in the distal fallopian tubes. 25 The IUI can be performed 24 hours after the hCG trigger if there is any suggestions that a premature LH surge has occurred based on a slowing of the rate of rise of estradiol levels in serum.

A single randomized study using two inseminations at 24 and 48 hours after the ovulating dose of hCG compared with a single insemination 36 hours after the hCG found a higher cycle fecundity with multiple inseminations per cycle.26 Risk of IUI 27 Uterine cramp, lower abdominal pain, vesovagal attack as the seminal plasma contains prostaglandins.

Pelvic infection by E. Coli due to use of fresh semen Veneral disease, HIV or hepatitis B or C. Failure of the treatment, since pregnancy rates per cycle are reported at anywhere between 5% and 25%.28 Induction of ovulation and controlled ovarian hyperstimulation: Ovulation induction (OI) and controlled ovarian hyper stimulation (COH) are the corner stone of infertility management. The goal of fertility treatment is to achieve a high pregnancy rate using safe, simple and inexpensive treatment protocols. Clomiphene citrate (CC), offers a simple, inexpensive and relatively safe choice of drug for treatment, but unfortunately, the

pregnancy rates are relatively low. Other drugs which are commonly used are Aromatase inhibitor (Letrozole), Gonadotrophins (rFSH and HMG), HCG. CC and hMG-hCG, Letrozole-hMG-hCG, Letrozole-rFSH-hCG, Gonadotrophins –hCG after pre-treatment with with a GnRHagonist. 12 The role of aromatase inhibitors in ovulation induction: Pharmacology and Mode of action: Letrozole are non steroidal selective aromatase inhibitors that have been approved for treatment for postmenopausal breast cancer since 1997.18 Aromatization of testosterone to estradiol and androstenedione to estrone is the last step in the biosynthesis of oestrogens.

Letrozole inhibits the conversion of adrenally generated androstenedione to estrone and estradiol by aromatase enzyme in peripheral tissue. It acts by competitive binding to the haem of cytochrome P450 subunit of the aromatase enzyme and interrupts the metabolism of oestrogen resulting in a decrease level of oestrogen in the body. As a negative feedback mechanism, the pituitary gland produces follicle stimulating hormone (FSH) leading to ovulation or superovulation. Therefore Letrozole mimics the action of CC but without depletion of oestrogen receptors.18 It possibly avoids the anti-oestrogenic effects, associated with clomiphene citrate.18 Their half life in plasma is around 2 days.

Dose Doses range from 5-7.5mgs, usually in two divided doses, by oral route. Should be taken daily for 5 days beginning on 2nd/3rd day of the cycle through 6th/7th day of cycle. Can also be started on 4th or 5th day of cycle and continued for a total of 5 days. 19 Side effects of Letrozole Generally well tolerated, the most common adverse effects are hot flushes, nausea and hair thinning.29 A greater number of new diagnosis of osteoporosis occurred among women receiving letrozole, but the long term effects on bone mineral density or lipid metabolism are yet to be determined.

Effectiveness of letrozole Monthly pregnancy success rate with the use of letrozole ovulation induction/IUI is 5%-12% per cycle. Multiple birth rates is about 10% with the majority being twins.19 Potential advantages of Aromatase inhibitor for Ovulation induction18 High pregnancy rate.

•

Monofollicular ovulation in most anovulatory patients.

•

High safety due to short half life and few adverse effects.

•

Reduced rate of multiple pregnancy

•

Reduced risk of severe

•

Ovarian Hyperstimulation syndrome

•

Reduced FSH dose required for controlled ovarian stimulation

•

Improved response to FSH in poor responders

•

Low cost of treatment

•

Convenience of administration: oral route, different regimens, including single-dose regimen

Induction of Ovulation with Human Gonadotrophins: For over 30 years, the only treatment used for gonadotrophins was human menopausal gonadotrophins, a gonadotrophin extracted from urine of menopausal women. A commercial preparation is still available, with either 75 units of FSH and 75 units of LH per ampoule or in an ampoule with twice the amount, 150 units of each gonadotrophin. Gonadotrophins are orally inactive, so must be given parenterally; the heavy protein content of the urinary preparation requires intramuscular injections.

A more purified urinary FSH preparation became available by removing most of the LH in the urinary product. This product still requires intramuscular injection. A more highly purified form is available which can be administered subcutaneously.

Recombinant FSH is now produced in Chinese hamster ovary cells transfected with the human FSH subunit genes.12 Recombinant FSH is homogenous and free of contamination by proteins (characteristic of menopausal gonadotrophins from urinary extracts); this allows subcutaneous administration.

Because of its structural and biologic similiarity to LH, HCG, readily available from human pregnancy urine and placental tissue, is used to stimulate the mid-cycle LH ovulatory search.

Recombinant HCG and recombinant LH are now available. These preparations will allow patient self-administration by subcutaneous injections. It is unlikely that the results will be different; however, it is possible that the risk of ovarian hyperstimulation will be reduced.

•

Preparation

•

Human menopausal gonadotrophins

•

Purified urinary FSH

•

Highly purified urinary FSH

•

Recombinant FSH

•

Human chorionic gonadotrophins

•

Recombinant HCG

•

Recombinant LH

•

Selection of patients for gonadotrophin treatment:

Demonstration of ovarian competence, tubal patency and uterine pathology should be evaluated, anovulation documented, and semen analysis obtained. Nongynaecological

endocrine problems must be treated, hypogonadotrophic function, galactorrhoea syndrome must be evaluated for intra-cranial lesion.12 How to use gonadotrophin therapy: A variable dosage method is used to achieve follicular growth and maturation. Follicle stimulation is achieved by 7-14 days of continuous gonadotrophins, one ampoule daily.

Response is assessed by degree of oestrogen produced by growing follicles. The patients were monitored periodically with the measurement of the circulating estradiol level and vaginal ultrasound assessment of the number and size of follicles. The patient is seen on the seventh day of treatment, and a decision is made to continue or increase the dose (step up method). After the seventh day, the patient is seen anywhere from daily to every one or two days. Another approach, the step down method, starts with a higher doe (2-3 ampoules) and reduces the dose to one ampoule after initial response, theoretically approximating the changes in FSH in a normal ovulatory cycle.

Patients with polycystic ovaries are handled more gently. The increased sensitivity to FSH is apparently due to the availability of a larger cohort of small follicles ready to respond to FSH (recruitable follicles). In these patients, assessment starts on the fourth or fifth day. Excessive stimulation in women with polycystic ovaries can be avoided by lower doses of gonadotrophins extended over a longer duration of treatment.

When estradiol and ultrasound monitoring indicate that the patient is ready to receive ovulatory stimulus, 5000-10,000 units of HCG are given as a single dose intramuscularly.

The patient is advised to have intercourse the day of the HCG injection, and two days afterward. In extremely hyposensitive ovaries, adequate follicular stimulation is required in doses of upto 4-6 ampules/day.

Pregnancy is usually achieved by administering gonadotrophins for 7-12 days.

Close supervision and experience is necessary to avoid difficulties.

Oestrogen Monitoring: The use of oestrogen measurements is necessary to choose the correct moment for administering the ovulatory dose of HCG in order to prevent hyperstimulation. Estradiol measurement starts on day 7 of cycle.

An estradiol window of 1000-1500 pg/mL is optimal. The risk of hyperstimulatio0n is significant from 1500-2000 pg/mL and, as a general rule, over 2000pg/mL. HCG should not be given, and the ovarian follicles should be allowed to regress.12 Ultrasound Monitoring 30 During normal cycles, the growing cohort of follicles can be identified by ultrasonography on days 5 to 7 as small sonolucent rays. The dominant follicle will become apparent by 8-10 days. Mean diameter of the follicle, indicating ovum maturity, varies from 20-24 mm (range 14-28 mm) in normal, spontaneous cycles. Pregnancies have not been observed with follicles <17mm in normal cycles. In 5-11% of cycles, two dominant follicles develop.

The potential signs of impending ovulation are: 31 â&#x20AC;˘

Presence of a dominant follicle (usually >16 to 18mm)

•

Anechoic area, double contour, around the follicle

•

Separation and folding of the follicle lining

•

Thickened proliferative endometrium

Fluid can be detected by frequently, but not always, the cul-de-sac. The follicle disappears, or reappears as a smaller, irregular cyst, which diminishes in 4-5 days.

It is claimed that a higher pregnancy rate can be achieved when ultrasound is combined with oestrogen monitoring. The guiding principle has been to administer HCG when mature follicles correlate with an oestrogen level of 200-400 pg/ mature follicle (>13 mm).This principle only applies to several leading follicles. We believe that HCG should not be administered if there are more than 3-5 follicles 13mm or greater in diameter. Mild hyperstimulaiton has been associated with an increased number of intermediate size follicles.

Measurement of Endometrial Thickness32 Studies in IVF cycles have revealed that successful implantation is correlated with endometrial thickness on the day of HCG administration. No pregnancies occurred when endometrial thickness was <6 mm. Chance of pregnancy is greatest if endometrial thickness is 9-10 mm or more.

Results with Gonadotrophin treatment A cumulative conception rate of 40% after 6 treatment cycles can be achieved in women with unexplained infertility. In randomized, controlled clinical trials the monthly pregnancy rates in couples with unexplained infertility is increased 2 to 3 fold (monthly fecundity rate of 9%) with clomiphene treatment and with human gonadotrophins the monthly fecundity rate is 1015% 33 The risk of ectopic pregnancy increases with ovulation induction, as a consequence of multiple oocytes and high hormone levels.34 Women with polycystic ovaries and moderate obesity require larger doses of gonadotrophins as compared to leaner women. A comparable pregnancy rate (40%) is achieved. However, spontaneous miscarriage is more frequent.

Complications: •

Hyperstimulation syndrome rate is 1-2 %.

•

Multiple pregnancies

•

Ovarian Hyperstimulation Syndrome (OHSS)

The incidence of clinically important hyperstimulation is striking, but mild type would be relatively common. The moderate to severe form appears at an impressive rate (1-2%). 35 Higher incidence of hyperstimulation is seen in IVF protocols, using combination of gonadotrophins and GnRH agonist.

Multiple pregnancies36

Multiple pregnancy rates were formerly reported as approximately 20-30% (triplets or more 5%). Currently, it can be as low as 10-20% with careful monitoring and good medical judgement. Spontaneous twins occur at only about 1%, and triplets 0.010-0.017%. Dizygotic twinning rate is inherited from the mother. Monozygotic twins occur at a rate of 0.03-0.04%.

In addition, miscarriage rate with gonadotrophins is higher (25%), probably due to effects of age, multiple pregnancies, and recognitions of early miscarriage.

Recent Studies on IUI and controlled ovarian hyperstimulation Mitwally and Casper have shown in their study that- Letrozole is more effective than Clomiphene citrate either alone or in combination with Gonadotrophins for ovulation induction or augmentation.19 Patients treated with Letrozole demonstrate low oestrogen production per follicle, around the physiological level with good follicular development, and with a lower incidence of multiple pregnancy. 18 When combined with Gonadotrophins, Letrozole reduces the dose of Gonadotrophins required for optimal follicular recruitment and improves the response to Gonadotrophin stimulation required in poor responders. 19 Compared to Clomiphene citrate groups, in Gonadotrophin combined uterine insemination cycles, the number of mature follicles and serum estradiol level on the day of hCG- were significantly lower in the Letrozole group, but the pregnancy rate is higher in the latter.37 In a randomized controlled trial in couples with unexplained non-conception, controlled ovarian stimulation (COS) in combination with IUI has been shown to result in significantly higher Cumulative pregnancy rate (PR) couple (33%) as compared to un stimulated intra Cervical insemination (10%), COS alone (19%) or IUI alone (18%) 33. The main benefit of the addition of COS to IUI is considered to be - induction of multifollicular growth (Cohlen, 1998)38. In a study by M.M.E. van Rumste et al, (2006) 39 32% of the couples conceived in four treatment cycles of COS- IUI. The pregnancy rate (PR per cycle in that study was 10.9%39. Two European societies for human reproduction and embryology (ESHRE) multicentre prospective studies compared ovulation induction alone with ovulation induction in conjunction with IUI, Intra peritoneal insemination (IPI), GIFT 36. In the treatment of unexplained infertility, the pregnancy rate achieved from-superovulation alone was less than when combined with IUI36, In a randomized controlled trial by F.P Hohmann and others(2001) low dose(75iu/dayof rFSH) initiated during early, mid and late follicular phaseled to multiple dominant follicle development.(overall in 60% cases) 40 Martinez et al in an extensive review. The English Literature from 1980 to 1999 showed that there was a marked variation in the result of IUI between different clinics. 41 Retrospective analyses of IUI data using life table analysis showed a relatively constant probability of becoming pregnant after each IUI treatment through four Gonadotrophin cycles. 42 In a study of Fertility Institute of New Orleans (1983-98)-has been shown that the probability of pregnancy per cycle-depends on age, sperm, quality, sperm source and number of preovulatory follicles that developed in response to Clomiphene citrate (CC), 43 and human menopausal Gonadotrophin (hMG) or follicle stimulating hormone (rFHS).44 Data from Bourn Hall Clinic (2007) showed a clinical pregnancy rate of 22% per stimulated IUI cycle.

IUI is one of the most popular treatments in our country. Mild to moderate male factor subfertility can be overcome by controlled ovarian stimulation and intra uterine insemination.

Although there are large number of study on IUI and COS internationally, but in our country there is no study at all.

The present study will be conducted to determine the follicular response by different types of ovulation inducing drugs in <30 and >30 age group of females, the conception rate in IUI in a tertiary level infertility management centre in our country.

Cost effectiveness of IUI and Ovulation induction In a large retrospective analysis of 45 published reports on the treatment of couples with unexplained infertility, Guzick et al.45 looked at the cost effectiveness of no treatment, CC alone, CC+IUI, hMG alone, hMG+IUI, IVF, and GIFT [26]. Analysis of data showed that CC+IUI was most cost effective (US$10,000 per pregnancy), compared to hMG+IUI (US$17,000 per pregnancy) and IVF (US$50,000 per pregnancy). In their conclusions, they state that â&#x20AC;&#x153;on the highest level of evidence found in the dataâ&#x20AC;? their recommendations of cost effective treatment for idiopathic infertility are: IUI does not seem to be effective without some form of superovulation, CC+IUI appears to be more cost effective than hMG+IUI; IVF and GIFT are effective for couples who have not conceived after superovulation +IUI. In a study in Netherlands by Goverde et al., 34 258 couples with a diagnosis of idiopathic or mild male-factor infertility were divided into three equal groups: 1) IUI alone, 2) IUI with mild ovarian hyperstimulation using low-dose FSH, and 3) IVF [27]. Their conclusion was that stimulated IUI was as effective as IVF in achieving a pregnancy (31% vs. 33%), and was more cost-effective than IVF- cost per pregnancy resulting in a single live birth was US $4,511-5,710 for stimulated IUI, versus US$ 14, 679 for IVF. They concluded that patients should be counselled that IUI for these two diagnostic groups offers as good a chance of achieving a pregnancy as IVF and is more cost-effective.

Materials and methods Methodology: Study Design- prospective study Place of study- The study was carried out in Centre for Assisted Reproduction (CARE), BIRDEM, Dhaka.

Duration of study- Starting from 10th May 2010 to 31st December 2010 Study Population- All infertility patients who attended CARE OPD BIRDEM and selected for IUI during the study period was included in the study.

Sample Size- Sample size was determined using the following formula n=z2pq/d2 Here, n=Desired sample size z=Standard normal deviate usually set at 1.96. q=1-p d= degree of accuracy is considered as .05.

Prevalence of infertility 15% p= .15 So sample n =

(1.96) 2 x .15 x .85 (.05) 2

= 195.92 = 196 So the estimated sample size was 196 in one year. But for the convenience and time constraint all the patients of outpatient department of CARE BIRDEM who underwent IUI during the period of 10th May 2010 â&#x20AC;&#x201C; 31st December 2010 was included in this study.

Total number of subjects, n=77.

Sampling technique: Purposive Sampling Method. All the OPD patients who were selected for IUI in CARE BIRDEM during this defined period were included.

Written informed consent was taken from the patients. Then a detailed history, physical examination and base line investigations were done in all infertile couples who attended the OPD, CARE BIRDEM. Subjects were selected by the following inclusion and exclusion criteria.

Inclusion criteria: Age of female < 40 years.

History of infertility at least > 2 years.

Unexplained infertility.

Mild to moderate male factor sub fertility with Total count

>10 million / ml

Motility grade A

> 10%

Morphology

>30% N

Polycystic ovary syndrome. {resistant to clomiphene} Mild endometriosis. {resistant to clomiphene} Male factor â&#x20AC;&#x201C; Erectile dysfunction, hypospadias Exclusion criteria: Bilateral tubal block.

Male factor subfertility where sperm count is <10 million / ml.

Age of the female partner >40 years.

Severe endometriosis.

No ovarian reserve.

Operational definition: Infertility: Inability to conceive after 1 year of regular unprotected coitus.

Primary infertility: When the couple has no history of conception.

Secondary Infertility: When they have been successful on at least one previous occasion (Henry G et al 1997).

Fecundability: Probability of achieving pregnancy within one menstrual cycle.

Fecundity: Ability to achieve a live birth after being exposed to the risk of pregnancy for one menstrual cycle (Crosignani et al 1993).

Unexplained infertility Term applied to a subfertile couple whose standard investigations yields normal results.

Chemical Pregnancy: A pregnancy diagnosed by positive Beta hCG titre that spontaneously aborts before clinical verification by other means such as TVS. Clinical Pregnancy: Pregnancy diagnosed by positive Beta hCG titre and clinically verified

by TVS (intra uterine sac or foetal cardiac activity) or in case of a miscarriage by pathologic examination.

Intra Uterine Insemination (IUI): It is the reproductive technique where processed and prepared semen is directly introduced into the uterine cavity by a specialized catheter.

Controlled ovarian hyperstimulation and IUI (COH-IUI): Induction of ovulation is done by clomiphene or letrozole or low-dose gonadotrophins, where monitoring of follicular growth is done by Trans vaginal sonography, followed by IUI. •

Oligozoospermia (Oligospermia): Sperm concentration <20 million/mL

•

Asthenozoospermia: Total motility<25% or forward progression<50.

•

Teratozoospermia: Normal morphology <50% (or <15% Kruger strict criteria).

•

Oligoasthenoteratozoospermia: Significant abnormalities of sperm.

•

Concentration, motility, and morphology.

•

Azoospermia: No spermatozoa in the ejaculate.

•

Aspermia: No ejaculate.

Variables of the study: Independent variable: Type and dose of ovulation inducing agent Dependent variable:

•

Follicular size

•

Endometrial thickness

•

Research instrument: A structured questionnaire was given to the respondent.

Study Procedure: Eligible infertile couples were selected. Informed consent was taken from them. Almost all the patients had some sort of past infertility treatments from various parts of the country. So categorization of these patients was very difficult. Thus there were no fixed selection criteria to determine which group of patient will be in letrozole group and which will be in combined letrozole and gonadotrophin group. Thus the patients were divided according to age.

Group A: Female with young age < 30 years.

Group B: Female with age > 30, up to 40 years.

Superovulation Protocol: Both groups of patients were stimulated by Letrozole 7.5 mg daily, started on D2 of the cycle and continued for 5 days. Patients were followed by this treatment for 3 cycles of IUI. Follicular response was assessed by TVS starting on D10 up to D14. When at least two follicles attained >18 mm size or single follicle >21 mm size then it was considered satisfactory. The patients who did not respond satisfactorily by 3 cycles of Letrozole were selected for combination of Letrozole and Gonadotrophins. These patients were stimulated

by Inj. Gonadotrophins (rFSH) 50 iu intra muscularly daily starting from D3 for 5-7 days (or more if required) + Letrozole 7.5 mg per day on D2 – D6. Folliculometry was done by TVS starting from D10 upto D14 (depending on response). If at least 2 follicle size > 18 mm or 1 follicle is >21 mm, Inj. rFSH was discontinued and Inj. HCG (pregnyl) 5000 IUI was given intra muscularly. A single insemination was performed 36 hours after the Inj. of hCG (pregnil or professy 5000 iu).

Intra uterine insemination Protocol: Semen specimens were collected by masturbation on site, evaluated according to standardized methods and prepared for IUI within 1 hr after collection. Semen was diluted 1:2 with HEPES buffered Ham’s F10 medium containing 1.5% serum albumin after centrifugation at 250 g for 10 min. The pillets were resuspended and combined in 3ml of medium and incubated for 1 hr. Appr. 0.05 ml was used to determine the concentration and motility of the sperm. 0.2-0.4 ml from the rest was drawn into the Shepard catheter, which is attached to 1 ml syringe. Then IUI was performed within 2.5 hrs of collection Follow up procedure: Patients were asked to attend the OPD of CARE BIRDEM 15 days after the missed period.

Positive pregnancy test result was defined as pregnancy. Pregnant patients were advised to come for regular antenatal checkup.

Ovulation induction and IUI were offered to the patients who did not conceive, for the next two cycles.

Main outcome measure: •

Number of the follicle 2-3

•

Size of the follicle >18 mm (if 2 or more), >21mm(1 or more) was considered satisfactory.

•

Endometrial thickness >7 mm.

Data Collection: Data was collected using a data collection sheet. Data from followup was aloso included in the data collection sheet. Follicular response was assessed by TVS report (D10 - D14) which showed number of the follicle, size of the follicle and endometrial thickness.

Data processing & analysis: Result of the study was calculated & analyzed by standard statistical methods by using SPSS (Statistical Package for Social Science) software, version 16 (SPSS, Inc. Chicago, IL, USA) and Excel windows programme. The data was expressed as mean±SD and median (range) as appropriate. Student’s unpaired t-test and Mann-whitney u test was used for calculating the difference between the groups. χ2 (chi square) test was performed to determine the clustering of different variable of interest. P value of less than 0.05 was considered statistically significant.

Ethical Consideration: It was a prospective study; all the subjects selected for the study were informed orally and in written about the study design, objectives, and the right for the participant to withdraw from the project at any time for any reason. Written consent was obtained from each subject. Then approval from the Ethical review board BIRDEM was obtained.

Observation and Results Fig 1

37 (48%) patients were in the <30 age group, and 40 (52%) patients were in the >30 age group.

Fig 2

15 (19%) suffered from infertility for <5 yrs, 30 patients (39%) suffered for 5-10 yrs, and 32 (42%) patients for >10 yrs. The mean duration of infertility was 9.4Âą4.7 yrs.

Fig 3

35 (45%) pts had normal FSH: LH ratio and 42 (55%) had an altered ratio.

Hyperprolactinaemia was present in 15 (20%) patients. 3 (4%) pts were hypothyroid

Fig 4

.Polycystic ovaries were present in 42 (55%) patients. Endometrial thickness was <6 mm in 50 (65%) patients. Endometriosis was present in 9 (12%) patients, while 6 (7%) patients had fibroid uterus Table 1 Patients Characteristics Values

Mean

SD

Age

31.08

±4.86

Duration of infertility

9.45

±4.59

Percentage (%)

Parity Nulliparous

77.92% (60 pts.)

Multiparous

22.8% (17 pts.)

Clinical Presentation Oligo/anovulation

74.02% (57 pts.)

Hyperandrogenism

14.28 % (11 pts.)

PCOS

55.05% (42 pts.)

BMI (weight in kg/m2)

22.7

±3.24

Mean age of the patients were 31.08 ±4.86 yrs. Mean duration of infertility is 9.45 ±4.59 yrs.

Mean BMI was 22.7±3.24.

Table 2 Effect of letrozole and combined letrozole and gonadotrophins on follicular size

Variables

Letrozole Group(n=77)

Combined Letrozole and Gonadotrophin Group (n=65)

No follicles

38 pts (49.36%)

Nil

Pts with follicle size 10-14mm

14 pts (18.9 %)

Nil

Pts with follicle size 14-18mm

13 pts (16.88 %)

15 pts (23.07%)

Pts with follicle size >18mm

12 pts (15.58 %)

50 pts (76.93%)

Variables

Letrozole (n=77)

Combined Letrozole and Gonadotrophin (n=65) t

Total no. of follicles

1.28±0.94

3.37±0.87

7.54

0.0001

(12 pts)3.54±1.63

(50 pts)3.44±1.93

0.37 4

0.71

5.93±1.06

5.93±1.07

5.37

0.67

7.14±1.70

8.61±1.4

5.83

0.0001

Duration of stimulation (days)

12.2±1.3

10.3±2.8

Ovulation/cycle

43/231 (18.6%)

174/195 (89.2%)

No. of mature follicles (>18mm) Pre-treatment thickness

endometrial

Post-treatment thickness

endometrial

χ2

208.1 7

P

0.0001

In letrozole group, mature follicles (>18 mm) developed in only 12 (15.58%) patients.

On the contrary, by giving gonadotrophins along with letrozole, mature follicles appeared in 50 (76.93%) patients.

Table 3

Outcome in letrozole and combined letrozole and gonadotrophins The mean of total no. of follicles in letrozole group is 1.28±0.94, whereas in combined letrozole and gonadotrophins group, the mean is 3.37±0.87.

Average duration of stimulation was 12.2±1.3 days for letrozole group, and 10.3±2.8 days for combined letrozole and gonadotrophins group. Ovulation/cycle was 18.6% in letrozole group and 89.2% in combined letrozole and gonadotrophins group Variables

Letrozole (n=77) (cycle=231)

Combined t Letrozole and Gonadotrophin (n=65) (cycle=195)

χ2

p value

Endometrial Thickness >7mm

37 pts (48%)

58 pts (90%)

25.16

0.0001

Endometrial Thickness <7mm

40 pts (52%)

7 pts (10%)

25.16

0.0001

Post-treatment thickness

7.14±1.70

8.61±1.4

endometrial

5.8 3

0.0001

Table 4 Endometrial thickness in letrozole and combined letrozole and gonadotrophin Endometrial thickness after treatment by letrozole was 7.14±1.70 mm, and post treatment endometrial thickness by combined letrozole and gonadotrophins was 8.61±1.4 mm, and p value was 0.0001, which is significant.

Table 5 Comparison of follicular response between two age groups (<30 yrs & >30 yrs) by letrozole Induction used – Letrozole (7.5 mg/ d for 5 days in a cycle) n=77

Variables

<30

>30

t test

χ2

P

No. of pt

37

40

No. of induction

111

120

Follicular size >18mm

8 pts (22%)

4 pts (10%)

0.34

0.74

Endometrial thickness(mm)

8.52

8.7

Ovulatory cycles (%)

28/111 (25%)

15/120 (12.5%)

3.82

0.051

Pregnancy rate/cycle (%)

9/111 (08%)

3/120 (03%)

2.63

0.11

Pregnancy patient rate

9/37 (24%)

3/40 (07%)

2.96

0.09

0.556

0.58

In >30 yrs group, only 4 (10%) patients had mature follicles, whereas in <30 yrs 8 (22%) patients had mature follicles. P value is 0.74, which is not

significant. Ovulatory cycle was 28/111 cycles in <30 yrs age group, and 15/120 cycles, in >30 yrs age group. P is 0.051 which is not significant.

Table 6 Comparison of follicular response between two age groups (<30 yrs and >30 yrs) by combined letrozole and gonadotrophins

Induction used – Inj. FSH (50 IU or hMG, 75 IU for 5-7 days in a cycle) (n=65) Variables

<30 yrs

>30 yrs

No. of pt

30

35

No. of induction

90

105

t test

χ2

P

Mean No. of follicles >18mm in a cycle 3.6±1.95

3.3±1.94

0.48 0.64

Follicular size >18mm in patients

20 pts (66%)

30 pts (86%)

1.31 0.2

Endometrial thickness(mm)

8.52

8.7

Ovulatory cycles (%)

83/90 (92%)

91/105 (86%)

0.99 0.32

Pregnancy rate/cycle (%)

16/90 (17%)

12/105 (12%)

1.11 0.29

Pregnancy patient rate

16/30 (54%)

12/35 (34%)

1.68 0.19

0.693

0.49

By combined letrozole and gonadotrophins in >30 yrs age group, 91

(86%) patients had mature follicles, whereas in <30 yrs age group, 83 (92%) patients had mature follicles. P value was 0.32 which is not significant.

Results: Total 77 patients were selected for IUI in CARE BIRDEM during the period of 10 th May to 31st December 2010. Observational analysis and results of interventional procedure and statistical analyses have been presented by tables and diagrams. All patients had some sort of past infertility treatment, at various levels from various parts of the country. Many of them came with documents of unsuccessful infertility treatment from renowned professionals in the field. Do the categorization of these patients were very difficult, thus there was no fixed selection criteria to determine which group patient will be included in (whether letrozole group or combined letrozole and gonadotrophins group). Therefore, patients were divided according to age.

Among 77 patients, 37 (48%) patients were in the <30 age group, and 40 (52%) patients were in the >30 age group. The mean age of patients was 31±4.8 yrs.

60(77.92%) patients had primary infertility, while 17 (22.08%) patients had secondary infertility. 15 (19%) suffered from infertility for <5 yrs, 30 patients (39%) suffered for 5-10 yrs, and 32 (42%) patients for >10 yrs. The mean duration of infertility was 9.5±4.6 yrs. 51 patients (66%) had only female factors responsible for infertility, 20 (26%) had only male factors, while 6 (8%) had both factors.

In female factor affected couples, 42 (82%) were suffering from PCOS. 23 (45%) patients were absolutely PCOS. Along with PCOS 10 (19%) had associated hyperprolactinaemia, 3 (6%) had hypothyroidism, and 6 (12%) had fibroid uterus. 9 patients were suffering from endometriosis, among whom 5 (10%) had associated hyperprolactinaemia.

Regarding the clinical presentation, 57 (74.02%) pts had irregular cycles ranging from oligoamenorrhoea to absolute amenorrhoea. Features of hyperandrogenism was present in 11 (14.28%) patients. 42 (55.05%) patients were diagnosed as PCOS by TVS and hormone assay. Mean BMI of patients were 22.7±3.24.

The actual causes of male infertility were not diagnosed properly, due to limitation of the centre. But the semen parameters have shown that 18 patients (23%) had oligozoospermia, 5 (7%) had asthenozoospermia, and 3 (4%) had oligoasthenozoospermia.

All females were evaluated for baseline (D2-D5) hormonal status and the results were as follows: 35 (45%) patients had normal FSH: LH ratio and 42 (55%) had an altered ratio.

Hyperprolactinaemia was present in 15 (20%) patients. 3 (4%) pts were hypothyroid..

Baseline TVS screening has shown that polycystic ovaries were present in 42 (55%) patients.

Endometrial thickness was <6 mm in 50 (65%) patients, and >6mm in 27 (35%) patients.

Endometriosis was present in 9 (12%) patients, while 6 (7%) patients had fibroid uterus All 77 patients were evaluated for tubal patency. Laparoscopy was used as a tool in 66 (86%) patients and HSG in 11 (14%) patients. Both tubes were patent in 59 (77%) patients, and one tube was blocked in 18 (23%) patients. During HSG assessment, Bicornuate uterus was found in 1 patient, and Arcuate uterus in another patient. During laparoscopy, ovarian drilling was done in all PCOS patients.

Ovulation induction was done in all 77 patients by giving letrozole 7.5 mg/day in two divided doses, starting from day 2 through day 6 of the cycle, and the effect was monitored by TVS on day 10-14. Follicular size and endometrial thickness was measured on 3 successive cycles.

Even after 3 cycles of letrozole, there was no follicular development in 38 (49.36%) patients.

10-14 mm sized follicle developed in 14 (18.9%) patients, and 14-18 mm sized follicles appeared in 13(16.88%) patients. Mature follicles developed in only 12 (15.58%) patients.

Patients who did not produce mature follicles were again selected for induction by letrozole 7.5mg on D2-D6 plus injection rFSH 50 iu on D3-D7, or D3-D10, as required. Monitoring was done by TVS on D10-14.

By giving combined gonadotrophins along with letrozole, mature follicles appeared in 50 (76.93%) patients. The mean of total number of follicles in letrozole group (n=77, cycle=231) is 1.28±0.94, whereas in combined letrozole and gonadotrophins group (n=65, cycle=195), the mean is 3.37±0.87. The mean of number of mature follicle with letrozole (12 pts) is 3.54±1.63, and in combined letrozole and gonadotrophins group (50 patients) mean number of mature follicles is 3.44±1.93. The p value is 0.0001, which is significant. Average duration

of stimulation in a cycle in letrozole group is 12.2±1.3 days. In combined letrozole and gonadotrophins group duration is 10.3±2.8 days. Ovulation per cycle was 18.6% in letrozole, and 89.2% in combined letrozole and gonadotrophins group. The p value is 0.0001, which is significant.

In letrozole group, endometrial thickness >7 mm was found in 37 (48%) patients. While in combined letrozole and gonadotrophins it was 58 (90%) pts. P value is 0.0001, which is significant. The mean of post treatment endometrial thickness in letrozole group is 7.14±1.70, while it is 8.61±1.4 in combined letrozole and gonadotrophins group. P value is 0.0001 which is significant.

When comparing the effect of letrozole in two age groups, in >30 yrs group, only 4 (10%) patients had mature follicles, whereas in <30 yrs 8 (22%) patients had mature follicles. P value is 0.74, which is not significant. Ovulatory cycle was 28/111 cycles, in <30 yrs age group, and 15/120 cycles, in >30 yrs age group. P is 0.051 which is not significant.

Pregnancy rate/cycle was 9/111 cycles in <30 yrs age group, and 3/120 cycles in >30 yrs age group. P value is 0.11, which is not significant. Thus there is no significant difference in follicular response by letrozole.

Among the 77 patients who were treated initially by letrozole, 12 patients were successful by letrozole. But the rest 65 patients were poor responders. Therefore combined letrozole (7.5 mg/ d for 5 days in a cycle) and gonadotrophins-Inj. rFSH (50iu.) for 5-7 days in a cycle) was given to these 65 patients. In >30 yrs age group, 30 (86%) out of 35 patients had mature follicles, whereas in <30 yrs age group, 20 (66%) out of 30 patients had mature follicles. P value is 0.2, which is not significant. In <30 yrs group, ovulatory cycle was 83/90 (92%), and in >30 yrs group it was 91/105 (86%). P value was 0.32 which is not significant.Therefore there is no significant difference in follicular response between two age groups by combined letrozole and gonadotrophins.

Among the 77 patients in Letrozole group, 12/231 cycles showed pregnancy,whereas among 65 couples in combined Letrozole and Gonadotrophin group, 28/195 cycles showed pregnancy.Pregnancy/cycle is 5.19% in letrozole group and 14.3% in combined Letrozole and Gonadotrophin group.Pregnancy patient rate was 12/77(16%) in Letrozole group and 28/65(43%) in combined group.P value is 0.0006 which is significant. There were no complications, like Hyperstimulation syndrome by low dose of Gonadotrophins.

Discussion: Induction of superovulation and intrauterine insemination are common treatments for couples with unexplained infertility and those with infertility associated with specific diagnoses in which no pregnancy has occurred despite standard diagnosis directed treatments. But here we studied couples of unexplained infertility, male factor infertility, immunological infertility, PCOS and couples with mild endometriosis. Total 77 patients were selected for IUI in our centre CARE BIRDEM. All patients had some sort of past infertility treatment, at various levels from various parts of the country. In the present study, mean age of female patient was 31±4.8 yrs. The mean duration of infertility was 9.5±4.6 yrs.

This result correlates with the other data which shows that fecundity in women at the age of 20 is approximately 15% to 20% per cycle – whereas the fecundity in infertile couples can be as low as 1% to 3%.46, 47 A marked decrease in fecundity with advancing age has been documented. Data from studies have suggested that fertility of women generally peaks

between ages 20 and 24, remains stable upto age of 30-32 and then begins to decline progressively.8.

Among 77 patients, 60 (77.92%) patients had been suffering from primary sub-fertility, and 17 (22.08%) patients had been affected by secondary sub-fertility.

The study correlates with Sarwat Jabeen(2002) which shows 64.89% primary infertility and 35.11% secondary infertility.

In this study, 51 patients (66%) had only female factors responsible for infertility, 20 (26%) had only male factors, and 6 (8%) had both factors. It also correlates with the meta-analysis

by WHO task force in 1992.9 In the broad Meta analysis of more than 20 trials studying infertile couples, the following primary diagnosis was found: disorders of ovulation (27%), abnormal semen parameters (or male factor infertility) (25%), abnormalities of the fallopian tube (22%), unexplained infertility (17%), endometriosis (5%) and others (4%).10 Screening for baseline hormonal status showed that 42 (55%) patients had an altered FSH: LH ratio. Hyperprolactinaemia was present in 15 (20%) patients. 3 (4%) pts were hypothyroid. Screening for diabetes showed that 66 (86%) patients were non-diabetic, while the rest 11 (14%) were diabetic. Baseline TVS screening has shown that polycystic ovaries were present in 42 (55%) patients. Endometrial thickness was <6 mm in 50 (65%) patients, and >6mm in 27 (35%) patients. Endometriosis was present in 9 (12%) patients; while 6 (7%) patients had fibroid uterus. This indicates that PCOS is the most important etiological factor among these patients, which is followed by male factor infertility.

As laparoscopy was used as a tool for tubal patency test in 66 (86%) patients, opportunity for therapeutic purpose (ovarian drilling) was availed in PCOS patients.

so the

In this study, even after 3 cycles of letrozole, there was no follicular development in 38 (49.36%) patients. 10-14 mm sized follicle developed in 14 (18.9%) patients, and 14-18 mm sized follicles appeared in 13(16.88%) patients. Mature follicles developed in only 12 (15.58%) patients. On the contrary by combined gonadotrophins and letrozole mature follicles appeared in 50 (76.93%) patients. The mean of total number of follicles in letrozole group (n=77, cycle=231) is 1.28±0.94, whereas in combined letrozole and gonadotrophins group (n=65, cycle=195), the mean is 3.37±0.87. The mean of number of mature follicle with letrozole (12 pts) is 3.54±1.63, and in combined letrozole and gonadotrophins group (50 patients) mean number of mature follicles is 3.44±1.93. The p value is 0.0001, which is significant. Average time interval for ovarian stimulation in letrozole group is 12.2±1.3 days.

In combined letrozole and gonadotrophins group duration is 10.3±2.8 days. Ovulation per cycle was 18.6% in letrozole, and 89.2% in combined letrozole and gonadotrophins group.

The p value is 0.0001, which is significant. In letrozole group, endometrial thickness >7 mm was found in 37 (48%) patients. While in combined letrozole and gonadotrophins it was 58 (90%) pts. P value is 0.0001, which is significant. The mean of post treatment endometrial thickness in letrozole group is 7.14±1.70 mm, while it is 8.61±1.4 mm in combined letrozole and gonadotrophins group. P value is 0.0001 which is significant. Among the 77 couples in Letrozole group, 12/231 cycles showed pregnancy, whereas among the 65 couples in combined letrozole and Gonadotrophins group, 28/195 cycles showed pregnancy. Pregnancy per cycle is 5.1% in letrozole group and 14.3% in combined letrozole and gonadotrophins group. Pregnancy patient rate is 12/77 (16%) in letrozole group, and in combined letrozole and gonadotrophins group, rate is 28/65 (43%). P value is 0.0006 which is significant.

In this present study, letrozole was associated with fewer developing and mature follicle, which is not comparable with the study by Mitwally & Casper 18, Al-Omari et al.48 who showed ovulatory rate by letrozole was 75% and 87.5%, respectively. Another study by Mitwally19 showed that treatment with letrozole+ FSH required less amount of FSH (616 IU vs. 1590 IU) than FSH alone , and the number of follicle >18mm was higher, in combined letrozle and FSH group (3.3 vs. 1.9, respectively) which is consistent with our study (3.37Âą0.87 vs. 1.28Âą0.94).

A prospective study comparing 3 treatment protocols letrozole+FSH, CC+FSH and FSH only in patients with unexplained infertility undergoing controlled ovarian hyperstimulation and IUI by Mitwally19 showed that the total FSH dose was lowest in letrozole+FSH group, but the endometrial thickness was highest in the letrozole+FSH group (9mm). The clinical pregnancy rate was highest in letrozole+FSH group (22.2%) which is comparable with our study, where pregnancy rate is 14.3% in combined letrozole and gonadotrophins group. The results of this study suggest that the addition of letrozole to FSH can reduce the dose of FSH and medication expense without detrimental effects on endometrial thickness and pregnancy.

In another study by Rumste 39 regarding COS and IUI in unexplained infertility showed that 32% of the couples conceived in four treatment cycles of COS-IUI which is within the range of 20-33% reported by others (Guzick et al.45). In other literatures by Crosignani91, Guzick et al.45, Dickey et al.44 pregnancy rate per cycle has been reported to vary from 9-20%. Several studies have been performed to search for plausible causes for these differences in pregnancy rate, and it has been shown that increasing maternal age, longer duration of non-conception and a poor semen quality have a negative impact on the pregnancy rate in couples receiving COS-IUI . In the literature there is controversy concerning the number of preovulatory follicles in COS-IUI and subsequent pregnancy rate.Tomlinson et al and Nuojua et al have shown an increase in pregnancy rate when follicle numbers rise,49 whereas Steures et al found that two follicles at the time of IUI did not increase the ongoing pregnancy rate as compared to one follicle 50. Although induction of multifollicular growth is expected to improve pregnancy outcome, it contains the risk of multiple pregnancies. Another study by Sarah Healey et al51 about the effect of letrozole and gonadotrophins in IUI patients showed that they required less gonadotrophin administration (median difference, 300 IU at 95% CI, 225375 IU) and had a thinner endometrium, (m df 1 mm), developed more follicles >14 mm (m df, 1 follicle 95% CI, 1-2 follicle). But the pregnancy rate did not differ between patients using gonadotrophins alone and those using gonadotrophins+ letrozole (20.9% vs. 21.6%).

Another study by Ganesh A, et al. 52, among 1387 clomiphene resistant PCOS patients showed that by letrozole, ovulation rate was 79.3% and with rFSH alone, it was 89.89%. PR in letrozole group was 23.39% vs. 17.92% in gonadotrophins group.

When comparing the effect of letrozole in two age groups, in >30 yrs group, only 4 (43%) patients had mature follicles, whereas in <30 yrs 8 (22%) patients had mature follicles. P value is 0.74, which is not significant. Ovulatory cycle was 28/111 cycles, in <30 yrs age group, and 17/120 cycles, in >30 yrs age group. P is 0.051 which is not significant.

Pregnancy rate/cycle was 9/111 cycles in <30 yrs age group, and 3/120 cycles in >30 yrs age group. P value is 0.11, which is not significant. Thus there is no statistical significance in follicular response and pregnancy rate by giving letrozole alone in these two age groups.

65 patients were poor responders to letrozole and were treated with combined letrozole and gonadotrophins. In >30 yrs age group, 31 (86%) out of 35 patients had mature follicles, whereas in <30 yrs age group, 20 (66%) out of 30 patients had mature follicles. P value is 0.2, which is not significant.Ovulatory cycles ,83/90(92%) in<30yrs and 91/105(86%) in >30

yrs age group.P value is 0.32 which is not significant. Therefore there is no significant difference in follicular response between two age groups by gonadotrophins. But >30 yrs age group required more doses of gonadotrophin (avg of 7-9 doses) than <30 yrs age group(avg of 4-5 doses).

In a study in Netherlands by Goverde et al. 34, 258 couples with a diagnosis of idiopathic or mild male-factor infertility were divided into three equal groups: 1) IUI alone, 2) IUI with mild ovarian hyperstimulation using low-dose FSH, and 3) IVF [27]. Their conclusion was that stimulated IUI was as effective as IVF in achieving a pregnancy (31% vs. 33%), and was more cost-effective than IVF- cost per pregnancy resulting in a single live birth was US $4,511-5,710 for stimulated IUI, versus US$ 14, 679 for IVF. They concluded that patients should be counseled that IUI for these two diagnostic groups offers as good a chance of achieving a pregnancy as IVF and is more cost-effective. Although there is no known national study regarding the follicular response by different types of ovulation inducing agents and efficacy of controlled ovarian stimulation and IUI and cost effectiveness of this treatment, interviews with different and renowned infertility management centres in our country have shown that cost of COH with Letrozole+IUI costs Tk. 10,000-15,000 per cycle, and COH with combined Letrozole and Gonadotrophins+IUI costs Tk. 20,000-27,000 per cycle, whereas IVF or ICSI costs Tk. 250,000-300,000, which is ten times more than COH+IUI, but success rate is comparable.

Summary: Intrauterine insemination with controlled ovarian hyperstimulation (COH-IUI) is a well known means to achieve pregnancy in unexplained and mild to moderate male factor infertility. This procedure is frequently used to treat subfertility patients in centre for assisted reproduction CARE BIRDEM. It is also inexpensive and easy to perform as office procedure.

The success rate is high.

It was a prospective study, carried out during the period of 10 th May -31st December, 2010 with an objective: To assess the follicular response by using Letrozole alone or a combination of Letrozole and Gonadotrophins in patients stimulated for IUI. To assess the follicular response between two age groups (upto 30yrs and above 30yrs) by using letrozole and combined letrozole and gonadotrophins in stimulated IUI patients All the 77 patients who were selected for IUI during this period, informed consent was taken from them, and then medical history and physical examination were done. They were stimulated by IUI letrozole alone for 3 cycles. Poor responders (n=65) were stimulated by combined letrozole and gonadotrophins.

Result: Mean follicular number was 1.28±0.94 in letrozole and 3.37±0.87 in combined letrozole and gonadotrophins. Number of follicles >18mm was found to be in 12 patients (3.54±1.63) of letrozole, and 50 patients (3.44±1.93) of combined letrozole and gonadotrophins. Pregnancy/cycle was 12/231 (5.19%) in letrozole and 28/195 (14.3%) in combined letrozole and gonadotrophins. Pregnancy patient rate is 12/77 (16%) in letrozole and in combined letrozole and gonadotrophins group rate was 28/65 (43%).

Conclusion: Number of mature follicle and pregnancy rate is higher in combined letrozole and gonadotrophins group than letrozole alone. There is no significant difference regarding follicular response and pregnancy rate in two age group.

Conclusion: The cause of infertility varies from country to country and in different social groups. In the developed country PCOS, Pelvic Endometriosis, Unexplained and male factor infertility maybe the main cause but the incidence of tubal occlusion caused by infection after childbirth or unsafe abortion and tuberculosis maybe an important cause in our country.

For the infertile couples in which the couple has no identifiable infertility factor and in PCOS resistant to clomiphene or letrozole alone and in mild endometriosis, and also in mild to moderate male factor infertility, the combination of superovulation and intrauterine insemination is an effective measure for achieving pregnancy. Moreover the effects of superovulation and IUI appear to be independent and additive. IUI and COS is an effective, non-invasive, relatively simple, less expensive than other higher ART and most suitable for unexplained and mild to moderate male factor infertility. It can be provided more easily to more infertile couples in office practices and general hospitals than can the more specialized techniques such as IVF. However, careful selection of patients is required for successful IUI. Studies by Goverde et al.34 on cost effectiveness of IUI and COS showed that it was as effective as IVF in achieving pregnancy (31% vs. 33%) and was more cost effective than IVF. So these two groups of patients should be counselled that IUI and COS is their preferable method, and there is least chance of complications like hyperstimulation syndrome, multiple pregnancy.

My study shows that number of mature follicle and pregnancy rate is higher in combined letrozole and gonadotrophins group than letrozole alone. There is no significant difference regarding follicular response and pregnancy rate in two age groups.

Limitations: •

The study period and population is very small

•

Most of the patients came with a history of long period of infertility with failure of different modalities of treatment

•

Many of the patients failed to maintain continuity of treatment and follow up (drop out).

•

Actual data about pregnancy outcome (chemical pregnancy, clinical pregnancy, miscarriage, ectopic pg) could not be obtained as the patients were reluctant to do follow up after achieving pregnancy

Recommendations: •

The study should be prospective, randomized and long term

•

Patient should be counselled properly for regular follow up

•

Patient should be counselled that achieving pregnancy is not the end of the treatment.

Further monitoring is essential for their treatment purpose as well as research.

•

Tertiary level infertility institution should be established so that the failed patients can go for higher assisted reproductive technologies.

References: Hamberger L, Nygren KG. Treatment of Infertility and its Historical context. Gynecological endoscopy and infertility, 1st Edition. Jaypee Brothers, Medical Publishers; 2005. P 3-4.

Bangladesh demographic Data Sheet and Survey-2007 World Health Organization. Infertility; a tabulation of available data on prevalence of primary & secondary infertility. Geneva, WHO, Programme on maternal & child health & family planning. Division on family health 1991.

Mosher WD. Pratt WF – The demography of infertility in the United States. In Asch RH, Stubb Jw, eds, Annual progress in reproductive medicine. Park Ridge, NJ: The Parthnon Publishing group, 1993: 37-43.

Abma JC, Chandra A, Mosher WD. Et el – Fertility, family planning & women’s health: new data from 1995 National survey of Family growth. Vital health stat 23, 1997: 1- 114.

Mehta RH, Anand Kumar TC. Declining semen quality in Bangaloreans: A preliminary report Curr Sci 1997; 72: 621.

Bangladesh Institute of Research in Promotion of Essential and Reproductive Health and Technologies (BIRPERH). Assesment of reproductive health care and review services provided at the level of thana, union and villages, August-1997 Issue, Vol-5.

Maroulis GB: Effect of ageing on fertility and pregnancy. Semin Reprod Endocrinol 9:165179, 1991 WHO scientific group report: recent advances in medically assisted conception. WHO technical report series 820. Geneva, WHO 1992.

Collins JA: Unexplained infertility. Keye WR, Chang RJ, Rebar RW, Soules MR (eds).

Infertility: Evaluation and treatment. Philadelphia, WB Saunders, 1995, P 249-262.

Dodson WC, Whitesides DB, Hughes CL, et al. Superovulation with washed intra-uterine insemination in the treatment of infertility: A possible alternative to gamete intra fallopian transfer and IVF. Fertil Steril 1987; 48: 441- 445 Dodson WC, Haney AF. Controlled ovarian hyperstimulation and intra-uterine insemination for treatment of infertility. Fertil Steril 1991; 55:457-467.

Corson GH, Kemmann E. The role of superovulation with menotropins in ovulatory infertility: a review. Fertil Steril 1991; 55: 468-477 Hamburg R, Insler V. Ovulation induction in perspective. Hum Reprod update 2002; 8: 449 – 462.

David S. Guzick, Sandran et al. Efficacy of super ovulation and intra uterine insemination in the treatment of infertility. National cooperative Reproductive medicine network, Massachusetts medical society – 1999. 340; 3: 177 – 183.

Brinsden PR and Dickey RP. An overview of intrauterine insemination and ovulation induction. Manual of intra uterine insemination and ovulation induction. Cambridge university press – 2010; ch – 1: p-1-6.

Aitken RJ, Clarkson JS. Cellular basis of defective sperm function and its association with the genesis of reactive O2 species by human spermatozoa. J. Reprod Fertil 1987; 81: 459 – 469.

Mitwally MF, Casper RF, Potential of aromatase inhibitors for ovulation and super ovulation induction in infertile women. Drugs 2006; 66 (17): 2149 – 60.

Mitwally MF, Casper RF, Aromatase inhibition improves ovarian response to follicle stimulating hormone in poor responders. Fertil steril 2002. April; 77 (4): 776 – 80.

Gregoriou O, Vlahos NF, Konidaris S et al. Randomized control trial comparing superovulation with letrozole vs. rFSH combined with IUI for couples with unexplained infertility who had failed clomiphene citrate stimulation and IUI. Vol. 90, Issue 3, 678-683, Sep 2008 WHO Scientific Group Report: Recent Advances in Medically Assisted Conception. WHO Technical Report Series 820. Geneva, WHO, 1992 Allen NC, Herbert CM 3rd, Maxson WS, et al. Intrauterine Inseminaiton: A critical review.

Fertil Steril 44: 569-580, 1985.

Cohlen BJ, Gerber-Schafer C, Wilhelm C, et al. Should we continue performing Intrauterine Inseminations in the year 2004? Gynecol Obstet Invest 59:3-13, 2004 Marrs RP, Vargyas JM, Saito H, et al. Clinical application of techniques used in human in IVF research. MJ Obstet Gynaecol 1983; 146:477-481Gomel V. From microsurgery to laparoscopic surgery: A progress. Fertil Steril, 1995; 63: 46468.

Oak MK, Chantler EN, Vaughan-Williams CA, Elstein M. Sperm survival studies in peritoneal fluid from infertile women with endometriosis and unexplained infertility. Clin Reprod Fertil 1985;3: 297-303 Silverberg KM, Johnson JV, Olive DL et al. A prospective randomized trial comparing two different IUI regiments in COH cycles. Fertil steril, 1992; 57: 357-361.

Mastroianni L, Laberge JL, Rock J. Appraisal of the efficacy of artificial insemination with husband’s sperm and evaluation of insemination technics. Fertil Steril 157; 8:260-266.

Mathieu C, Ecochard R, Bied V, et al: Cumulative conception following intrauterine artificial insemination with husband’s spermatozoa: influence of husband’s age. Human Reprod 10: 1090-1097, 1995.

Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Eng J Med 2003; 348:24312442.

Timor-Tritsch IE, Rottem S (eds). Transvaginal sonography, 2nd ed. NY,Elsevier, 1991.

Jaffe R, Ben-Aderet N. Ultrasonic screening in predicting the time of ovulation. Gynaecol Obstet, Invest 1984;18:303

Smith B, Porter R, Ahuja K, Craft I. Ultrasonic assessment of endometrial changes. J Invitro Fertil Embryo transfer 1984; 1: 233-238.

David S. Guzick, Sandran et al. Efficacy of super ovulation and intra uterine insemination in the treatment of infertility. National cooperative Reproductive medicine network, Massachusetts medical society – 1999. 340; 3: 177 – 183.

Goverde AG, McDonnell J, Vermeiden JP. IUI or IVF in idiopathic subfertility: A randomized trial and cost effectiveness analysis. Lancet 2000; 355: 13-18.

Navot D et al. Ovarian hyperstimulation syndrome in novel reproductive technologies. Fertil Steril 1992; 58: 249-261.

ESHRE Capri Workshop Group (2000) Multiple Gestation Pregnancy. Hum Reprod 15, 1856-1864.Chan PT, Schlegel PN: Diagnostic and therapeutic testis biopsy. Curr Urol Rep 1:266-272, 2000.

Jee BC, KU SY, Suh cs, et al. Use of Letrozole versus clomiphene citrate combined with Gonadotrophins in IUI cycles; a pilot study, Fertil steril 2006 June; 85 (6): 1774 – 7.

Cohlen BJ (1998) Intra uterine insemination and controlled ovarian hyper stimulation.

Templeton AA, Cookze I and O’Brien PMS (eds) Evidence – based fertility treatment.

RCOG press, London, PP 205 – 216.

Rumste MME, Hartog JE, Dum oulin JCM, etal. Is controlled ovarian stimulation in intra uterine insemination an acceptable therapy in couples with unexplained non conception in the perspective of multiple pregnancies? Hum. Reprod ; Vol – 21: No – 3, P – 701, 2006.

Hohmann F.P, Laven JSE, De Jong FH, Eijkemans MJC and Fauser BCJM. Low dose exogenous FSH initiated during the early, mid or late follicular phase can induce multiple dominant follicle development Hum reprod 2001; vol. 16: No – 5, P – 846 – 884 Martinez AR, Bernardus RE, Vermeiden JPW. Factors affecting pregnancy results after intrauterine insemination. Hum Reprod 1988; Abstract – 35.

Remohi J, Gastaldi C, Parisio P. Intrauterine insemination and controlled ovarian hyperstimulation in cycles before GIFT. Human Reprod 1989; 4:918-920.

Dickey RP, Taylor SN, et al. Effect of diagnosis, age, sperm quality, number of pre ovulatory follicles on the outcome of multiple cycles of clomiphene citrate & intrauterine insemination.

Fertil steril 2002; 78: 1088 – 95.

Dickey RP, Taylor SN, LU PY, et al. Risk factors for high order multiple pregnancy and multiple birth after controlled ovarian hyper stimulation; results of 4062 intrauterine insemination cycles. Fertil steril 2005; 83: 671 – 83.

Guzick DS, Carson SA, et al (1999). Efficacy of super ovulation and intra uterine insemination in the treatment of infertility. National cooperative Reproductive Medicine network. New Engl. J. Med 340. 177 – 183.

Lenton EA, Weston GA, Cook IA. Long term followup of the apparently normal couple with a complaint of infertility. Fertil Steril 1977; 28: 913-919.

Templeton AA, Penny GC. The incidence, characteristics and prognosis of patients whose infertility is unexplained. Fertil Steril 1982; 37:175-182.

Al-Omari WR, Sulaiman W, Al-Hadithi. Comparison of two aromatase inhibitors in women with PCOS. Intern J Gynaecol Obstet 2004; 85 : 289-291 Smith B, Porter R, Ahuja K, Craft I. Ultrasonic assessment of endometrial changes. J Invitro Fertil Embryo transfer 1984; 1: 233-238.

Enoujua HS, Gissler M, Martikainen et al. Obstetric and perinatal outcome of pregnancies after IUI. Hum Reprod 1999; 14:2110-2115 Steures P, Van DSJW, Mol BW et al. Prediction of an ongoing pregnancy after IUI. Fertil Steril 2004; 82: 45-51Goverde AG, McDonnell J, Vermeiden JP. IUI or IVF in idiopathic subfertility: A randomized trial and cost effectiveness analysis. Lancet 2000; 355: 13-18.

Sarah Healey, Seang LT, Togas T, et al. Effects of letrozole on superovulation with gonadotrophins in women undergoing IUI. Fertil Steril; 80: 1325-1329. Dec 2003 Ganesh A, Goswami SK, Chattopadhyay, Chaudhury K, Chakrabarty BM. Comparison of letrozole with continuous gonadotrophins and clomiphene gonadotrophin combination for ovulation induction in 1387 PCOS women after clomiphene citrate failure: A randomized prospective clinical trial.

J of asst. repro gent. 2/09 January 26(1): 19-24.

List of Abbreviations: ART – Assisted Reproductive Technology IUI – Intra Uterine Insemination COH-IUI – Controlled ovarian hyperstimulation-Intra Uterine Insemination FSH – Follicle stimulating Hormone LH – Luteinizing Hormone GnRH – Gonadotrophin releasing Hormone hCG – Human Chorionic Gonadotrophin hMG – Human Menopausal Gonadotrophin rFSH – Recombinant Follicle stimulating Hormone IVF-ET – Invitro Fertilization and Embryo transfer GIFT – Gamete Intra fallopian transfer ZIFT – Zygote Intra fallopian transfer Cc – Clomiphene Citrate TVS – Trans vaginal Sonography TSH – Thyroid stimulating Hormone OHSS – Ovarian hyperstimulating Syndrome